What is Curebase?
Founded in 2017 and headquartered in San Francisco, Curebase is a pioneering healthtech firm dedicated to accelerating medical innovation. The company addresses the inefficiencies inherent in traditional clinical research by empowering physicians to enroll patients directly within their local communities. Through the deployment of cutting-edge clinical software and remote study management techniques, Curebase is effectively reinventing the research process from the ground up. By bridging the gap between patients and life-saving medical advancements, the company serves as a critical infrastructure provider for the modern pharmaceutical and biotech industries, ensuring that clinical trials are more accessible, efficient, and representative of diverse patient populations.
How much funding has Curebase raised?
Curebase has raised a total of $55M across 2 funding rounds:
Series A
$15M
Series B
$40M
Series A (2021): $15M with participation from GGV Capital, Xfund, and Bold Capital
Series B (2022): $40M led by GGV Capital, Positive Sum, Xfund, Industry Ventures, World Innovation Lab, Acrew Capital Management, and BOLD Capital Group
Key Investors in Curebase
GGV Capital
A global venture firm with a multi-stage, sector-focused approach, GGV Capital invests in high-growth companies across social, enterprise, and smart technology sectors.
Positive Sum
An early-stage investment firm that provides long-term capital and strategic support to founders building transformative companies in sectors like data engineering and technology.
Xfund
An early-stage venture capital partnership between leading firms and research universities, focusing on multidisciplinary innovation emerging from academic environments.
What's next for Curebase?
Looking ahead, the strategic deployment of the $40M investment will likely focus on enhancing the company's proprietary software platform and expanding its network of participating clinical sites. As the industry shifts toward decentralized and hybrid trial models, Curebase is uniquely positioned to capture significant market share by reducing the time and cost associated with drug development. The company's focus on operational excellence and technological integration suggests a future roadmap centered on scaling its remote study capabilities and fostering deeper partnerships with global research institutions. With a solid foundation of institutional backing, Curebase is poised to remain at the forefront of the digital health revolution, driving systemic improvements in how medical breakthroughs are validated and brought to market.
See full Curebase company page
